Atrial tachycardia (AT) downregulates L-type Ca 2ϩ current (I CaL ) and causes atrial fibrillation-promoting electric remodeling. This study assessed potential underlying signal transduction. Cultured adult canine atrial cardiomyocytes were paced at 0, 1, or 3 Hz (P0, P1, P3) for up to 24 hours. Cellular tachypacing (P3) mimicked effects of in vivo AT: decreased I CaL and transient outward current (I to ), unchanged I CaT , I Kr , and I Ks , and reduced action potential duration (APD). I CaL was unchanged in P3 at 2 and 8 hours but decreased by 55Ϯ6% at 24 hours. Tachypacing caused Ca 2ϩ i accumulation in P3 cells at 2 to 8 hours, but, by 24 hours, Ca 2ϩ i returned to baseline. Ca v 1.2 mRNA expression was not altered at 2 hours but decreased significantly at 8 and 24 hours (32Ϯ4% and 48Ϯ4%, respectively) and protein expression was decreased (47Ϯ8%) at 24 hours only. Suppressing Ca 2ϩ i increases during tachypacing with the I CaL blocker nimodipine or the Ca 2ϩ chelator BAPTA-AM prevented I CaL downregulation. Calcineurin activity increased in P3 at 2 and 8 hours, respectively, returning to baseline at 24 hours. Nuclear factor of activated T cells (NFAT) nuclear translocation was enhanced in P3 cells. Ca 2ϩ -dependent signaling was probed with inhibitors of Ca 2ϩ /calmodulin (W-7), calcineurin (FK-506), and NFAT (INCA6): each prevented I CaL downregulation. Significant APD reductions (Ϸ30%) at 24 hours in P3 cells were prevented by nimodipine, BAPTA-AM, W-7, or FK-506. Thus, rapid atrial cardiomyocyte activation causes Ca 2ϩ loading, which activates the Ca 2ϩ -dependent calmodulin-calcineurin-NFAT system to cause transcriptional downregulation of I CaL , restoring Ca 2ϩ i to normal at the cost of APD reduction. These studies elucidate for the first time the molecular feedback mechanisms underlying arrhythmogenic AT remodeling. (Circ Res. 2008;103:845-854.) Key Words: atrial fibrillation Ⅲ electrophysiological remodeling Ⅲ arrhythmia mechanisms Ⅲ antiarrhythmic therapy A trial fibrillation (AF) is the most common clinical tachyarrhythmia, with an incidence that increases with age and a significant association with cardiovascular morbidity and mortality. 1 AF causes electrophysiological changes, primarily resulting from the rapid atrial activation rates, that promote arrhythmia perpetuation. 2,3 Atrial action potential (AP) duration (APD) shortening is a major contributor to refractoriness abbreviation, which is, in turn, a primary factor in AF promotion. 4,5 Loss of APD and impaired APD rate adaptation are largely attributable to the associated I CaL reduction. 4, 6 Atrial remodeling is believed to have important therapeutic implications, and there is interest in developing antiremodeling therapies, 7 but this approach is limited by an insufficient understanding of underlying mechanisms to allow for the definition of molecular targets. There is indirect evidence for a role of Ca 2ϩ overload in the remodeling caused by atrial tachycardia (AT), 8, 9 and transcriptional downregulation of the Ca v 1.2 I CaL ␣-subunit contributes to I CaL downregulation. 5,10 However, the signaling mechanisms coupling Ca 2ϩ loading to I CaL downregulation are poorly understood. In this study, we used an in vitro model of paced canine atrial cardiomyocytes to assess (1) whether it mimics in vivo AT-induced cellular electrophysiological remodeling; and (2) if so, what intracellular signaling mechanisms are involved.
Cell Culture
Cells were plated at low density (Ϸ10 4 cells/cm 2 ) onto laminincoated (20 g/mL) glass coverslips and maintained at 37°C. After 4 hours, dead and unattached myocytes were removed and fresh medium was added. 12 Pacing was accomplished with square wave, 5-ms pulses. Parallel 24-hour culture studies were performed with cells subjected to 1-Hz (P1) and 3-Hz (P3) pacing and no pacing (P0). For time course studies, results with 1-and 3-Hz pacing were compared to each other at each time point and to prepacing baseline. After cell culture with or without pacing, cells were transferred to superfusion baths for ionic current or AP recording or harvested and frozen for subsequent biochemical study. In some experiments, 1 mol/L nimodipine, 10 mol/L BAPTA-AM, 1 mol/L W-7, 5 mol/L FK-506, or 10 mol/L INCA-6 was added to the culture medium and thoroughly washed out before recording currents or [Ca 2ϩ ] i . Cell viability was measured by Trypan blue dye exclusion.
Ionic Current and AP Recording
All in vitro recordings were obtained at 37°C. The whole-cell perforated-patch technique was used to record APs and tight seal patch clamp to record ionic currents. Junction potentials averaged 15.9 mV and were corrected for APs only. For solution contents for recording of specific ionic currents and APs, see the expanded Materials and Methods section in the online data supplement.
Calcium Transients
Atrial cardiomyocytes were incubated with indo-1 AM (5 mol/L) in 100 mol/L pluronic F-127 and 0.5% DMSO for 3 to 5 minutes and then superfused with Tyrode's solution. Ultraviolet light passing through a 340-nm interference filter was reflected into a ϫ40 oil immersion fluor objective for excitation of intracellular indo-1. Exposure of the cell to UV light was controlled with an electronic shutter to minimize photobleaching. Emitted light was reflected into a spectral separator, passed through parallel filters at 400 and 500 nm (Ϯ10 nm), detected by matched photomultiplier tubes, and electronically filtered at 60 Hz. Chamber background fluorescence was removed by adjusting the 400-and 500-nm channels to 0 over an empty field of view near the cell. Fluorescence signal ratios were digitized and converted to [Ca] i as previously described. 13 Cells were paced with 10-ms 1.5-times threshold-voltage pulses. 13 
Calcineurin Activity and NFAT Imaging
Atrial cardiomyocyte samples were collected prepacing and after 2, 8, or 24 hours of 1-or 3-Hz pacing. Calcineurin phosphatase activity was measured with a commercial assay kit (Calbiochem). Atrial cardiomyocyte samples were homogenized in lysis buffer. Calcineurin activity was measured in phosphatase standard buffer and determined as the dephosphorylation rate of the R-II peptide. Free phosphate released from R-II peptide was measured at 620 nm.
To measure nuclear and cytoplasmic NFAT (nuclear factor of activated T cells) immunofluorescence, cells were fixed with 2% paraformaldehyde in PBS, blocked, and permeabilized with PBS containing 2% normal donkey serum, 2% BSA, and 0.1% Triton X-100. Cells were then incubated overnight at 4°C with primary antibodies (monoclonal mouse anti-NFATc3 and polyclonal rabbit anti-NFATc4, 1/200 in PBS with 1% normal donkey serum, 1% BSA, and 0.05% Triton-X100). Donkey anti-mouse Alexa fluor (emission peak, 555-nm) and donkey anti-rabbit Alexa fluor (488 nm) were corresponding secondary antibodies. Cells were then exposed to RNaseA (100 g/mL) for 25 minutes at 37°C, followed by 3 washes and then incubated with ToPro3 for nuclear contour definition (1 mol/L) for 45 minutes. Images were obtained with a Zeiss LSM-510 confocal microscopy system and deconvolved with point-spread functions acquired with the same parameters as the images of interest. Nuclear and cytosolic NFATc3 and NFATc4 staining was quantified from the total number of pixels within the corresponding region normalized to area. Measurements were obtained in 5 Z-stacks covering the maximum nuclear area to calculate mean densities for each cell.
Quantitative Real-Time PCR
Total RNA was isolated from 100-to 300-mg atrial cardiomyocyte samples with TRIzol, followed by chloroform extraction and isopropanol precipitation, DNase treatment, and quality control with polyacrylamide gel electrophoresis. 14 First-strand cDNA was synthesized from 2 g of total RNA with High Capacity cDNA Archive Kits. Real-time quantitative PCR (QPCR) was performed with 6-carboxy-fluorescein-labeled fluorogenic Ca v 1.2 TaqMan primers and probes and TaqMan universal master mix. Fluorescence signals were detected in duplicate, normalized to 18S ribosomal RNA, and quantified with MxPro QPCR software.
Western Blot Analysis
Paced atrial cardiomyocyte samples were homogenized in radioimmunoprecipitation assay buffer as previously described. 15 The homogenate was centrifuged (15 000 rpm, 20 minutes, 4°C). The supernatant was used for protein concentration measurement by Bradford assay with BSA as a standard. For ␣1c subunit assessment, 40-g protein samples were separated by 8% Na-dodecylsulfate polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and incubated with rabbit anti-cardiac Ca v 1.2, 1:100 and mouse antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:20 000), followed by goat anti-mouse (1:2000) or goat anti-rabbit (1:5000) horseradish peroxidaseconjugated secondary antibodies. Signals were visualized with Western Lightning Chemiluminescence Reagent Plus and quantified by videodensitometry.
Data Analysis
Clampfit 9.2, GraphPad Prism 4.0, IgorPro5.04B, MxPro-Mx 3000P, SPSS, and Origin 5.0 were used for data analysis. All data are expressed as meansϮSEM. Multiple group statistical comparisons were obtained by 2-way ANOVA, and individual group mean differences were evaluated by Student's t tests with Bonferroni correction. A 2-tailed PϽ0.05 was considered statistically significant.
Results

AP Changes
Cell capacitance averaged 142Ϯ7, 144Ϯ8, and 148Ϯ8 pF (nϭ35 per group; PϭNS) in P0, P1, and P3 cells, respectively. Cell viability averaged Ϸ50% in P0 and P1 cells and was reduced to Ϸ30% in P3 cells (supplemental Table I ). Cell dimensions (supplemental Table I ) and morphologies (online data supplement, Figure I ) did not change with tachypacing. After 24 hours of pacing at 0, 1, or 3 Hz, APs were recorded at frequencies between 0.1 and 2 Hz, allowing 1 minute at each frequency to reach steady state. Resting membrane potential and AP amplitude were not altered by tachypacing. Resting membrane potential averaged Ϫ72.5Ϯ2.1 mV (nϭ14 cells) in P0 cells compared with Ϫ74.1Ϯ1.5 mV (nϭ16) and Ϫ74.1Ϯ0.9 mV (nϭ19) in P1 and P3 cells, respectively (PϭNS). AP amplitude at 1 Hz averaged 114Ϯ2 mV (nϭ14 cells) in P0 cells, 112Ϯ2 mV (nϭ16) in P1 cells, and 108Ϯ3 mV (nϭ19) in P3 cells (PϭNS). Figure 1A shows representative APs recorded at 1 Hz from P0, P1, and P3 cardiomyocytes. APD 90 (APD to 90% repolarization) was significantly reduced and APD rate adaptation blunted in P3 cells ( Figure  1B ). APDs were not significantly different in P0 versus P1 cells.
Ionic Current Changes
Ca 2؉ Currents Figure 2A shows I CaL recordings on 200-ms depolarizing steps from Ϫ50 to ϩ10 mV. I CaL density was significantly decreased by 24-hour tachypacing at test potentials between Ϫ10 mV and ϩ40 mV ( Figure 2B ). For example, I CaL at ϩ10 mV averaged Ϫ5.0Ϯ0.5 pA/pF (nϭ13), Ϫ4.8Ϯ0.6 pA/pF (nϭ16), and Ϫ2.0Ϯ0.1 pA/pF (nϭ13) in P0, P1, and P3 cells, respectively. I CaL inactivation voltage dependence was determined with 1000-ms prepulses to voltages between Ϫ90 and ϩ50 mV, followed by 300-ms test pulses to ϩ10 mV. Activation voltage dependence was obtained from data obtained as illustrated in Figure 2B , based on the relation I v ϭI max (VϪV r )(G v /G max ), where I v and G v are current and conductance at voltage V; I max and G max are maximum current and conductance, and V r is the reversal potential. V r was determined from the horizontal axis intercept of the ascending limb of the I CaL -voltage relation. The voltage dependencies of I CaL activation and inactivation were unaffected (Boltzmann fits) in tachypaced cells ( Figure 2C ). Voltage (V 1/2 ) for half-maximum activation averaged Ϫ3.1Ϯ0.7 (nϭ13), Ϫ3.5Ϯ0.9 (nϭ16), and Ϫ3.6Ϯ0.8 mV (nϭ13) in P0, P1, and P3 cells, respectively (PϭNS). The inactivation V 1/2 averaged Ϫ19.3Ϯ0.8 (nϭ11), Ϫ18.8Ϯ1.4 (nϭ12), and Ϫ17.4Ϯ0.5 (nϭ12) mV in P0, P1, and P3 cells, respectively (PϭNS). Biexponential I CaL inactivation time constants were unchanged by pacing ( Figure 2D ). Time-dependent recovery was well fitted by monoexponential functions, with time constants averaging 46.9Ϯ2.4 ms (nϭ12 cells), 41.9Ϯ2.2 ms (nϭ13), and 42.7Ϯ4.1 ms (nϭ10) in P0, P1, P3 cells (PϭNS; Figure 2E ).
Recordings used to obtain low-voltage-activated T-type calcium current (I CaT ) are shown in supplemental Figure IIA. As previously described, 4 I CaT was analyzed by subtracting currents recorded with a holding potential of Ϫ90 mV from currents in the same cell at a holding potential of Ϫ50 mV. Mean I CaT density-voltage relations are shown in supplemental Figure IIB . I CaT density was unaffected by changing pacing frequency during the 24-hour culture period. For example I CaT at Ϫ20 mV averaged Ϫ1.30Ϯ0.1 pA/pF (nϭ15), Ϫ1.25Ϯ0.1 pA/pF (nϭ20), and Ϫ1.28Ϯ0.1 pA/pF (nϭ19) in P0, P1, and P3 cells, respectively (PϭNS). Current-voltage relations showed no differences among groups, suggesting no differences in voltage dependence.
Transient Outward Current
I to recordings from P0, P1, and P3 cells are shown in supplemental Figure IIIA. I to was significantly reduced by tachypacing (supplemental Figure IIIB) . For example, I to at ϩ40 mV averaged 7.6Ϯ0.5 (nϭ20) pA/pF, 7.6Ϯ0.6 pA/pF (nϭ18), and 3.5Ϯ0.4 pA/pF (nϭ19) in P0, P1, and P3 cells, respectively. The overall form of the current-voltage relation did not change. The approach used in Figure 2C was applied to determine I to activation voltage dependence, with the I to reversal potential based on tail currents following 2.2-ms activating pulses to ϩ50 mV averaging Ϫ71Ϯ2 mV, Ϫ73Ϯ4 mV, Ϫ70Ϯ2 mV (nϭ5 cells per group) in P0, P1, P3 cells (PϭNS). Activation V 1/2 based on data fits in each experiment (supplemental Figure IIIC) averaged 9.5Ϯ1.6 (nϭ17), 9.4Ϯ1.1 (nϭ15) and 10.7Ϯ1.9 mV (nϭ13) in P0, P1, and P3 cells (PϭNS). Inactivation voltage dependence was studied with 1000-ms prepulses from Ϫ70 mV, followed by 200-ms test pulses to ϩ60 mV. Boltzmann fit inactivation V 1/2 averaged Ϫ24.9Ϯ1.2 (nϭ22 cells), Ϫ26.7Ϯ0.9 (nϭ21), and Ϫ26.7Ϯ1.4 mV (nϭ19) in P0, P1, and P3 (PϭNS) cells (supplemental Figure IIIC) . The time constants of I to inactivation curves, which were well fitted by monoexponential relations, showed no differences (supplemental Figure IIID) .
Inward Rectifier and Delayed Rectifier K ؉ Currents
Supplemental Figure 
Intracellular Calcium Responses
The results presented in Figures 1 and 2 and supplemental Figures II and III suggest that the isolated cell model recapitulates the principal cellular electrophysiological features of atrial tachycardia remodeling: reduced APD and APD rate adaptation, decreased I CaL and I to , and unchanged I CaT , I Kr , and I Ks . 4 A commonly accepted explanation of the mechanism of atrial tachycardia remodeling invokes a negative-feedback response to protect against Ca 2ϩ overload via the downregulation of I CaL . 2 However, no direct evidence to support this notion has been presented. Our system allows for the measurement of [Ca 2ϩ ] i and I CaL as a function of in vitro pacing duration, permitting an evaluation of the relative changes in each component. We therefore recorded [Ca 2ϩ ] i and I CaL in parallel sets of cells from the same batches that were either not tachypaced (P1) or were paced at 3 Hz (P3) for 2, 8, or 24 hours. Figure 3A shows examples of [Ca 2ϩ ] i transients measured at 1 Hz from cells that had been subjected Figure 3E . Mean I CaL remained unchanged during up to 8 hours of tachypacing but decreased significantly at 24 hours ( Figure 3F ). I CaL inactivation kinetics (supplemental Figure IVA) and voltage dependence (supplemental Table II) were not affected by tachypacing. The time course of peak I CaL changes is illustrated in Figure 3G , and indicates that reductions in I CaL correspond temporally to the restoration of baseline [Ca 2ϩ ] i values. No changes in I CaL were observed over time in P1 cells (supplemental Figure V) . These results provide evidence for a molecular feedback loop that involves cellular sensing of [Ca 2ϩ ] i loading, coupling to regulatory mechanisms that reduce I CaL and Ca 2ϩ loading, resulting in a restoration of cellular Ca 2ϩ balance. We therefore turned our attention to the intracellular signaling mechanisms that sense Ca 2ϩ loading and cause I CaL downregulation.
Mechanisms of I CaL Downregulation
We first addressed the mechanism for I CaL downregulation. There is evidence that in vivo atrial tachycardia downregulates I CaL via decreases in ␣ 1c subunit mRNA expression. 4, 15 We therefore applied QPCR to measure Ca v 1.2 mRNA expression in P1 and P3 cells subjected to various pacing durations. Ca v 1.2 mRNA expression was significantly decreased, by 32Ϯ4% and 48Ϯ4%, respectively, after 8 and 24 hours of 3-Hz pacing (Figure 4A, right) . Ca v 1.2 protein expression was not significantly altered at 2 or 8 hours but was reduced significantly at 24 hours ( Figure 4B ; examples of Western blots in supplemental Figure VI) , by 47Ϯ8%, in P3 cells. The changes in Ca v 1.2 mRNA and protein expression were specifically related to tachypacing because neither was altered significantly in P1 cells (Figure 4 , left).
Analysis of Ca 2؉ -Dependent Pathways
The data described above point to a Ca 2ϩ -dependent pathway that is triggered by increased [Ca 2ϩ ] i , leading to reductions in Ca v 1.2 mRNA within 8 hours, which results in decreased Ca v 1.2 protein expression and diminished I CaL within 24 hours. If this presumed system is correct, prevention of intracellular Ca 2ϩ loading in response to 3-Hz pacing should prevent I CaL downregulation. We tested this idea in 2 ways. First, we exposed P0, P1, and P3 cells throughout 24-hour pacing to 1 mol/L nimodipine to suppress Ca 2ϩ entry via I CaL . Consistent with the hypothesized role of Ca 2ϩ entry in I CaL downregulation, nimodipine prevented I CaL decreases in P3 cells ( Figure 5A ). In additional studies, we added 10 mol/L BAPTA-AM to the culture medium for the 24-hour-pacing period to buffer [Ca 2ϩ ] i . Once again, I CaL downregulation was prevented in P3 cells ( Figure 5B ). Nimodipine and BAPTA-AM also controlled intracellular Ca 2ϩ loading, as indicated by Ca 2ϩ imaging (supplemental Figure VII) . We then turned our attention to potential Ca 2ϩ -dependent signaling pathways. Calmodulin is a key Ca 2ϩ -binding protein that senses intracellular Ca 2ϩ concentration and modulates a wide range of Ca 2ϩ -dependent enzyme systems. 16 We used the calmodulin inhibitor W-7 to address the potential importance of calmodulin in coupling [Ca 2ϩ ] i increases to downstream effectors. Atrial cardiomyocytes were subjected to P0, P1, or P3 conditions for 24 hours in the presence of 1 mol/L W-7. Calmodulin inhibition completely suppressed I CaL downregulation in P3 cells ( Figure 5C ). Furthermore, calmodulin inhibition prevented downregulation of Cav1.2 transcript expression by tachypacing (supplemental Figure VIIIA) .
Calcineurin is a Ca 2ϩ -dependent protein phosphatase that plays a key role in a variety of cardiac-remodeling processes, 17 including the regulation of ion channel expression. 18 We studied potential calcineurin involvement by adding the calcineurin blocker FK-506 (5 mol/L) to the medium of P0, P1, and P3 cells during 24-hour pacing. FK-506 prevented I CaL downregulation ( Figure 5D ), as well as tachypacinginduced Cav1.2 transcript downregulation (supplemental Figure VIIIB) . We then measured calcineurin-related phosphatase activity over time in cells exposed to 1-or 3-Hz pacing. No significant changes in calcineurin activity were observed in P1 cells ( Figure 4C ). In contrast, calcineurin activity was increased significantly at 2 and 8 hours of tachypacing in P3 cells. This time course indicates that calcineurin activity is rapidly increased by intracellular Ca 2ϩ loading and that calcineurin activity increases precede decreases in Ca v 1.2 mRNA, consistent with a calcineurin-dependent signal that causes downregulation in mRNA expression.
Calcineurin dephosphorylates cytoplasmic NFAT transcription factors, promoting their translocation into the nucleus, where they participate in transcriptional regulation. 19 We used deconvolved confocal microscopic immunofluores- cent images to quantify cellular localization of the NFAT isoforms NFATc3 and NFATc4. Figure 6A shows examples of NFATc3, NFATc4, and merged images (with ToPro3 to define the nucleus) in P1 and P3 cells. Figure 6B shows quantification of the nuclear/cytoplasmic staining ratios. Whereas P1 and P0 cells showed similar nuclear/cytoplasmic staining, P3 cells showed stronger nuclear staining localization, consistent with nuclear translocation. If NFAT-dependent tran- Table II ) was altered with cell pacing. Consistent with nuclear NFAT translocation playing a key downstream role in Cav1.2/I CaL downregulation, interventions acting higher up in the signaling cascade (BAPTA-AM, W-7, and FK-506) all suppressed NFAT translocation ( Figure 6C through 6E). Interestingly, despite the fact that W-7 and FK-506 prevented transcriptional downregulation of I CaL , they did not adversely affect cell Ca 2ϩ indices; on the contrary, they prevented Ca 2ϩ transient increases with 8-hour P3 pacing (supplemental Figure IX) .
Prevention of APD Changes
One potential interest of delineating the signal transduction processes involved in rate-dependent remodeling would be to design new strategies to prevent arrhythmogenic APD shortening. As a proof of principle, we studied the effects on cultured-myocyte APD of inhibiting various components of the signaling system. Figure 7A shows APs recorded at 1 Hz from P1 and P3 cells exposed to nimodipine, BAPTA-AM, W-7, or FK-506 throughout the 24-hour pacing period. Figure  7B shows corresponding meanϮSEM data for P0, P1, and P3 cells. The results indicate that prevention of Ca 2ϩ loading, suppression of calmodulin signaling, or inhibition of calcineurin prevents tachycardia-induced APD abbreviation.
There might be concern that prevention of I CaL downregulation could have negative effects on cell viability by enhancing Ca 2ϩ overload. On the contrary, interventions that prevented I CaL downregulation were found also to prevent the deterioration in cell viability (supplemental Table I ) and Ca 2ϩ overload (supplemental Figure VII 
Discussion
In the present study, we explored the cell-signaling that causes APD abbreviation and I CaL downregulation in an in vitro model of atrial tachycardia remodeling. The results suggest that I CaL downregulation results from a molecular feedback system that detects intracellular Ca 2ϩ loading via the Ca 2ϩ /calmodulin system, which activates calcineurin, which, in turn, stimulates nuclear translocation of NFAT, resulting in transcriptional downregulation of Ca v 1.2 that decreases Ca 2ϩ load by reducing I CaL , with APD reduction as a consequence.
Comparison With Previous Studies of Atrial Tachycardia Remodeling
Decreased I CaL is a consistent feature of atrial tachycardia remodeling and is believed to contribute importantly to the APD abbreviation that shortens refractoriness and promotes AF. 4, 6, 20 I CaL reduction is associated with decreased Ca v 1.2 mRNA expression, 5, 10, 15, 21 and many investigators have also noted decreases in Ca v 1.2 protein expression. 10, 21, 22 A role for Ca 2ϩ loading in atrial tachycardia remodeling was first suspected based on the protective effects of I CaL blockers against short-term remodeling. 8, 23 Subsequent work showed that atrial cardiomyocyte Ca 2ϩ loading begins within several minutes of the onset of cellular tachypacing. 24 Cell ultrastructure changes point to transient Ca 2ϩ overload in atria of goats with AF. 9 Short-term tachypacing of rat atria augments nuclear NFAT expression and causes changes in BNP and c-fos expression, effects that are prevented by cyclosporin-A. 19 Bukowska et al showed calcineurin expression and activity upregulation in atrial tissues from AF patients, in association with nuclear translocation of NFAT and increased hypertrophic gene expression. 25 Calcineurin-related changes were reproduced by ex vivo pacing (2 to 4 Hz) of human atrial tissue slices. 25 Lin et al presented additional evidence for in vivo activation of the calcineurin and NFAT pathways in an atrial tachypacing porcine AF model. 26 These previous studies suggest that atrial tachycardia causes Ca 2ϩ loading, induces transcriptional downregulation of Ca v 1.2, and can activate calcineurin-dependent mechanisms. Our study is the first to demonstrate directly causative links between atrial cardiomyocyte tachycardia, cellular Ca 2ϩ loading, I CaL downregulation, calcineurin activation, NFAT translocation, and associated APD alterations. A schematic representing our findings is presented in Figure 8 . 
Ca 2؉ /Calmodulin and Calcineurin-Mediated Ion Channel Regulation
The Ca 2ϩ /calmodulin system is an important cardiomyocyte Ca 2ϩ sensor that responds to intracellular Ca 2ϩ changes on both a beat-to-beat and tonic basis. 27 Ca 2ϩ /calmodulin binding activates a variety of downstream mediators, including calcineurin and Ca 2ϩ /calmodulin kinase II. Neonatal rat cardiomyocyte tachystimulation activates calcineurin/NFAT signaling. 28 Calcineurin is a Ca 2ϩ -activated serine/threonine phosphatase composed of a catalytic A subunit (56 to 63 kDa) and a regulatory B subunit (19 kDa) 17 that dephosphorylates a number of cytoplasmic proteins, including the regulatory domains of NFATc3 and NFATc4, which translocate into the nucleus and regulate gene transcription. 29, 30 NFAT is a particularly important mediator of responses to changes in intracellular Ca 2ϩ patterns. 31 Calcineurin/NFAT signaling alters transcriptional regulation of I to , with most studies showing I to downregulation, 18,32-34 although upregulation has also been observed in neonatal rat cardiomyocytes. 35 I CaL is increased in calcineurin-overexpressing mice, but this effect appears to be related to hypertrophy rather than to direct effects on the I CaL system. 36 We did not observe hypertrophic responses in tachystimulated atrial cardiomyocytes. Previous in vitro models of atrial tachycardia remodeling have included rapidly paced HL-1 cells derived from a mouse atrial tumor cell line, 38 and paced human atrial tissue slices. 25 The HL-1 cell model displays important features of atrial remodeling but is limited by a low expression rate of I CaL (Ͻ20% of cells display prominent I CaL ) and K ϩ channel remodeling (unchanged I to , increased I Kr ) 38 that differs from the established pattern of in vivo atrial tachycardia remodeling (reduced I to , unchanged I Kr ). 4, 20, 37 The human tachypaced atrial slice model reproduces some biochemical features seen in AF patients, but its electrophysiological properties have not been established, and atrial tissue superfusion is known to cause important functional alterations and viability problems. 39 One potentially important change that we did not observe in tachypaced cardiomyocytes was inward rectifier K ϩ current enhancement. 37 A possible explanation for this is that inward rectifier K ϩ current enhancement develops more slowly than the other changes, not having been noted with Ͻ7-day atrial tachyarrhythmia. 40 Tachypaced cardiomyocytes in our model did not show cellular hypertrophy, consistent with previous studies of atrial cells from dogs subjected to up to 42-day tachypacing. 4 Atrial cells from patients with persistent AF may be hypertrophied, 6 possibly because of underlying cardiac disease or the effects of greater AF chronicity, a difference that must be considered in interpreting our findings.
Considerations of the Model
Potential Significance of Our Observations
To our knowledge, our study is the first to explore in detail the molecular signaling underlying atrial tachycardia cellular electrophysiological remodeling. Atrial tachycardia remodeling has significant clinical consequences. 2, 3 Suppression of atrial remodeling is a promising target for AF therapy development, 7,41 but a major limitation to therapeutic innovation in this area is a lack of clear information about underlying molecular mechanisms. The cellular signaling underlying atrial tachycardia remodeling defined in the present study is, therefore, of considerable potential significance. Furthermore, we have shown that inhibition of key steps in the signaling chain can prevent remodeling-induced AP changes that are important in AF promotion. Interestingly, interventions that suppressed I CaL downregulation improved Ca 2ϩ i loading and cell viability, suggesting that the signaling cascade producing I CaL downregulation may not effectively prevent Ca 2ϩ overload and cell damage and may actually produce counterproductive consequences. This is a novel observation with potentially important implications for the management of AF and the development of antiremodeling therapies. In addition to identifying potential targets for antiremodeling therapy, we have established a cellular model of atrial tachycardia remodeling that may be useful for further investigations of the underlying cellular and molecular biology.
